317338-46-8

Basic information

• Product Name: (1,4-Dioxa-spiro[4.5]dec-8-YL)-acetic acid Methyl ester
• Synonyms: (1,4-Dioxa-spiro[4.5]dec-8-YL)-acetic acid Methyl ester;Methyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate;METHYL 1,4-DIOXASPIRO[4.5]DECANE-8-ACETATE
• CAS NO: 317338-46-8
• Molecular Formula: C₁₁H₁₈O₄
• Molecular Weight: 214.25822
• Mol File: 317338-46-8.mol

Chemical Properties

• Boiling Point: 292.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1,4-Dioxa-spiro[4.5]dec-8-YL)-acetic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (1,4-Dioxa-spiro[4.5]dec-8-YL)-acetic acid Methyl ester(317338-46-8)
• EPA Substance Registry System: (1,4-Dioxa-spiro[4.5]dec-8-YL)-acetic acid Methyl ester(317338-46-8)

Safety Data

• Hazardous Substances Data: 317338-46-8(Hazardous Substances Data)

Upstream product

• 172270-85-8 8-(methoxyformylmethylene)-1,4-dioxaspiro[4.5]decane 
• 67-56-1 methanol 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 135761-76-1 2-(1,4-dioxaspiro[4.5]decan-8-yl)ethanol 
• 1124174-16-8 methyl 2-((1r,4r)-4-hydroxycyclohexyl)acetate 
• 1268239-62-8 C₂₆H₂₉F₂N₃O₅ 
• 1268239-16-2 trans-6-[3-(2,3-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester 
• 1268239-40-2 trans-6-[3-(2-chloro-3-methyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester 
• 1268239-60-6 6-nitro-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-methoxycarbonylmethyl-cyclohexyl ester 
• 1268239-61-7 6-amino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-methoxycarbonylmethyl-cyclohexyl ester 
• 1268239-14-0 trans-6-[3-(2,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester 
• 1268239-64-0 C₂₆H₂₉F₂N₃O₅ 
• 1268239-88-8 C₂₇H₃₂ClN₃O₅ 
• 518345-32-9 2-( 1,4-dioxaspiro[4.5]decan-8-yl)ethyl 4-methylbenzenesulfonate 
• 1187750-00-0 4-(3,3-dicyano-6,6,6-trifluorohexyl)cyclohexanone 
• 1187749-86-5 1-(3,3-dicyano-6,6,6-trifluorohexyl)-4-ethynyl-4-fluorocyclohexane 
• 1187749-85-4 1-(3,3-dicyano-6,6,6-trifluorohexyl)-4-ethynyl-4-hydroxycyclohexane 

Relevant articles and documents

Pentamethylphenyl (Ph*) and Related Derivatives as Useful Acyl Protecting Groups for Organic Synthesis: A Preliminary Study

A study of acyl protecting groups derived from the Ph? motif is reported. While initial studies indicated that a variety of functional groups were not compatible with the Br 2-mediated cleavage conditions required to release the Ph? group, strategies involving the use of different reagents or a modification of Ph? itself (Ph*OH) were investigated to solve this problem.

NOVEL TETRAHYDROISOQUINOLINE COMPOUNDS

The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides trans-6-[3-(2,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-is

NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides a compound represented by the general formula (I), or pharmacologically acceptable salt thereof: [wherein, R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents a group represented by the formula -C(=O)-O-R4 or the like; R4 represents a hydrogen atom, a C1-C6 alkyl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group B, or the like; X represents an oxygen atom, a methylene group, or a group represented by the formula -NH-, or the like; L represents a single bond, a methylene group, or the like;...... represents a single bond or a double bond; m represents 1 or 2; n represents an integer of 0 to 5; Substituent Group A represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, or the like; and Substituent Group B represents a C3-C6 cycloalkyl group, a phenyl group, a carboxyl group, or the like].

Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors

Discovery and optimization of a piperidyl benzamide series of 11β-HSD1 inhibitors is described. This series was derived from a cyclohexyl benzamide lead structures to address PXR selectivity, high non-specific protein binding, poor solubility, limited in

SUBSTITUTED BICYCLOLACTAM COMPOUNDS

The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5a, R5b, R5c, R5d, Q, A, Z, and R7 /s

DISPIRO TETRAOXANE COMPOUNDS

A compound having the formula (I) wherein ring A represents a substituted or unsubstituted monocyclic or multicyclic ring; m=any positive integer; n=0-5; X=CH and Y=-C(O)NR1R2, -NR1R2 or -S(O)2R4, where R1, R2 and R4 are each individually selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring, or any combination thereof, or R1 and R2 are linked so as to form part of a substituted or unsubstituted heterocyclic ring, or X=N and Y=-S(O)2R3 or -C(O)R3, where R3 is selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted amine, substituted or unsubstituted carbocyclic ring, substituted or unsubstituted heterocyclic ring or any combination thereof.

Benzamide derivatives and uses related thereto

Benzamide derivatives of formulae I and II, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof, and pharmaceutical compositions comprising the same, are described and have therapeutic utility, particularly in the treatment of diabetes, obesity, and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are defined as provided herein.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.